Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04219007 · ClinicalTrials.gov registry record · Phase 2
Vosoritide for Selected Genetic Causes of Short Stature
A Phase 2 study of Short Stature, sponsored by Andrew Dauber.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04219007 is a Phase 2 study of Short Stature that is active but no longer recruiting, run by Andrew Dauber. The registered enrollment target is 56 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04219007, a Phase 2 study of Short Stature, is active but no longer recruiting, sponsored by Andrew Dauber.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team hypothesizes that patients with selected genetic causes of short stature that interact with this pathway will benefit from treatment with vosoritide, a CNP analog, a selective NPR-B agonist which directly targets the growth plate. This study will enroll patients with short stature in selected genetic categories and will follow them for a 6 month observation period to obtain a baseline growth velocity, safety profile and quality of life assessment. Patients will then be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes.
Conditions Studied
Interventions
- DRUG Vosoritide
Study Locations (1)
District of Columbia
- Children's National Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2035-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04219007
The ClinicalTrials.gov registry entry for NCT04219007 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew Dauber, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Short Stature appearing as the primary indexed condition, and to 1 intervention - of which Vosoritide is the first listed.
NCT04219007 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04219007 about?
NCT04219007 is a clinical study titled "Vosoritide for Selected Genetic Causes of Short Stature". Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team hypothesizes that patients with selected genetic causes of short stature that interact with this pathway will b...
What is the current status of trial NCT04219007?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2020-08-04. Estimated completion is 2035-06-01.
What conditions does trial NCT04219007 study?
This clinical trial studies the following conditions: Short Stature.
What interventions are being tested in trial NCT04219007?
The interventions under investigation include: Vosoritide (DRUG).
Who is sponsoring clinical trial NCT04219007?
This trial is sponsored by Andrew Dauber, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04219007 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Stature
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.